A detailed history of Telemus Capital, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Telemus Capital, LLC holds 1,899 shares of VRTX stock, worth $952,766. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,899
Previous 1,891 0.42%
Holding current value
$952,766
Previous $657,000 17.5%
% of portfolio
0.06%
Previous 0.06%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 01, 2024

BUY
$343.0 - $410.68 $2,744 - $3,285
8 Added 0.42%
1,899 $772,000
Q3 2023

Oct 25, 2023

SELL
$338.18 - $362.46 $1,690 - $1,812
-5 Reduced 0.26%
1,891 $657,000
Q2 2023

Jul 10, 2023

BUY
$314.42 - $351.91 $11,319 - $12,668
36 Added 1.94%
1,896 $667,000
Q1 2023

Apr 11, 2023

SELL
$283.23 - $323.1 $25,490 - $29,079
-90 Reduced 4.62%
1,860 $586,000
Q4 2022

Jan 11, 2023

BUY
$285.76 - $321.48 $190,030 - $213,784
665 Added 51.75%
1,950 $0
Q3 2022

Oct 11, 2022

SELL
$273.83 - $305.53 $33,681 - $37,580
-123 Reduced 8.74%
1,285 $372,000
Q2 2022

Aug 10, 2022

SELL
$234.96 - $292.55 $13,627 - $16,967
-58 Reduced 3.96%
1,408 $397,000
Q1 2022

Apr 06, 2022

BUY
$221.42 - $260.97 $102,296 - $120,568
462 Added 46.02%
1,466 $383,000
Q4 2021

Feb 01, 2022

BUY
$177.01 - $223.45 $177,718 - $224,343
1,004 New
1,004 $220,000
Q4 2020

Jan 28, 2021

SELL
$207.01 - $276.09 $702,798 - $937,325
-3,395 Closed
0 $0
Q3 2020

Nov 02, 2020

BUY
$255.65 - $303.1 $17,384 - $20,610
68 Added 2.04%
3,395 $740,000
Q2 2020

Jul 17, 2020

BUY
$225.48 - $295.8 $14,205 - $18,635
63 Added 1.93%
3,327 $980,000
Q1 2020

Jun 05, 2020

BUY
$199.77 - $247.81 $652,049 - $808,851
3,264 New
3,264 $940,000
Q1 2018

Apr 27, 2018

SELL
$151.6 - $177.13 $7,580 - $8,856
-50 Closed
0 $0
Q4 2017

Feb 02, 2018

BUY
$137.28 - $155.55 $6,864 - $7,777
50
50 $7,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Telemus Capital, LLC Portfolio

Follow Telemus Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Telemus Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Telemus Capital, LLC with notifications on news.